DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 13 full-time employees. The firm is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. The company has developed a proprietary drug product for the treatment of ADHD called Methydur.

Industry: Pharmaceutical Preparations Peers: Lyra Therapeutics Inc CorMedix Inc ImageneBio Inc Johnson & Johnson MariMed Inc Paratek Pharmaceuticals, Inc. scPharmaceuticals Inc. TFF Pharmaceuticals, Inc. Verrica Pharmaceuticals Inc